Paul Benny Net Worth

The estimated Net Worth of Paul S. Benny is at least $204 Thousand dollars as of 1 January 2023. Paul Benny owns over 1,041 units of SeaSpine Corp stock worth over $203,918 and over the last 2 years he sold SPNE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Benny SPNE stock SEC Form 4 insiders trading

Paul has made over 1 trades of the SeaSpine Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 1,041 units of SPNE stock worth $9,931 on 1 January 2023.

The largest trade he's ever made was exercising 1,041 units of SeaSpine Corp stock on 1 January 2023 worth over $9,931. On average, Paul trades about 260 units every 0 days since 2022. As of 1 January 2023 he still owns at least 21,375 units of SeaSpine Corp stock.

You can see the complete history of Paul Benny stock trades at the bottom of the page.

Paul Benny biography

Paul Benny is the VP, Corp. Controller, Assistant Treasurer & Assistant Sec. at SeaSpine Corp.

What's Paul Benny's mailing address?

Paul's mailing address filed with the SEC is 5770, Armada Drive, Carlsbad, San Diego County, California, 92008, United States.

Insiders trading at SeaSpine Corp

Over the last 9 years, insiders at SeaSpine Corp have traded over $2,659,931 worth of SeaSpine Corp stock and bought 297,805 units worth $3,591,897 . The most active insiders traders include Stuart Essig, Richard E Caruso, and Keith Valentine. On average, SeaSpine Corp executives and independent directors trade stock every 39 days with the average trade being worth of $151,762. The most recent stock trade was executed by John J. Winge on 1 January 2023, trading 4,868 units of SPNE stock currently worth $46,441.

What does SeaSpine Corp do?

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.

Complete history of Paul Benny stock trades at SeaSpine Corp

SeaSpine Corp executives and stock owners

SeaSpine Corp executives and other stock owners filed with the SEC include:

• Keith Valentine,
  President, Chief Executive Officer, Director
• Keith C. Valentine,
  Pres, CEO & Director
• John Bostjancic,
  Chief Financial Officer, Senior Vice President, Treasurer
• Tyler Lipschultz,
  Senior Vice President, Orthobiologics and Business Development
• Patrick Keran,
  Vice President, General Counsel, Secretary
• John Winge,
  Vice President of Sales
• John J. Bostjancic,
  Sr. VP, CFO & Treasurer
• Patrick L. Keran,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Beau Standish P.Eng., Ph.D.,
  Pres of Enabling Technologies
• Kimberly Commins-Tzoumakas,
  Independent Director
• Renee Gaeta,
  Independent Director
• Kirtley Stephenson,
  Independent Non-Executive Chairman of the Board
• Stuart Essig,
  Lead Independent Director
• Michael Fekete,
  Independent Director
• Keith Bradley,
  Independent Director
• John Henneman,
  Independent Director
• Dennis Cirino,
  Senior Vice President, Global Spinal Systems
• Hollis Winkler,
  Sr. VP of HR
• Patrick L. Keran J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Frank Vizesi,
  Chief Scientific Officer
• Shaeffer Bannigan,
  Sr. Director of Product Devel.
• Paul Benny,
  VP, Corp. Controller, Assistant Treasurer & Assistant Sec.
• Dr. Beau Standish Ph.D.,
  Pres of Enabling Technologies
• Dennis L. Cirino,
  Sr. VP of Global Spinal Systems
• Tyler P. Lipschultz,
  Sr. VP of Orthobiologics & Bus. Devel.
• John J. Winge,
  VP of Sales
• Carrie Mendivil,
  Head of Investor Relations
• James M Sullivan,
  Director
• Cheryl R Blanchard,
  Director
• Brian D. Baker,
  VP, Global Operations
• Richard E Caruso,
  10% owner
• Shweta Maniar,
  Director
• Life Sciences Corp Integra ...,
  
• Beau Standish,
  President, Enabling Tech
• Angela Steinway,
  Director